BioSpace Spotlights Northern California's Life Science Community

Print and online campaign highlights the area's leading companies

DENVER, Sept. 1, 2011 /PRNewswire/ -- Today BioSpace, the leading life sciences employment and news website, launched the 2011-2012 Biotech Bay™ Hotbed Campaign, marking the 16th edition.

(Logo: http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO )

The campaign highlights leading organizations across Northern California. Each company's brand is added to an electronic and printed campaign map that is promoted online as well as at industry events and career fairs.

"In 1989 BioSpace celebrated Northern California as the first major biotechnology cluster with the release of the Biotech Bay Hotbed map. Today the program features campaigns in nine Hotbed regions," said Mike Tansey, chief executive officer at onTargetjobs, the parent company of BioSpace. "We're proud to continue to showcase Northern California's thriving life science region and connect thousands of specialized professionals through the program's promotions and resources."

See the inaugural Biotech Bay map on display at the Smithsonian Institution's National Museum of American History in Washington D.C.

The 2011-2012 campaign sponsors include Roche Molecular Systems, Pfizer, Bio-Rad Laboratories, Bayer Healthcare, MedImmune, Novartis Vaccines & Diagnostics, and Gilead Sciences; participant companies include Dynavax Technologies Corporation, InterMune, Celera, Nektar Therapeutics, Onyx Pharmaceuticals, Jennerex and more.

About BioSpace.com

BioSpace.com is the leading, online resource for industry careers, news and resources. For 25 years, BioSpace has helped accelerate recruitment, communication and discovery among business and scientific leaders within the life sciences.

An onTargetjobs, Inc. company, BioSpace powers DeviceSpace.com, an information and recruitment resource for the medical device and diagnostics industries, as well as ClinicaSpace.com, a similar resource for clinical research markets.

SOURCE BioSpace.com

Suggested Articles

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.